SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin
SPECT/CT imaging of HER2 expression in colon cancer-bearing nude mice using 125I-Herceptin
复制标题
使用 125 I-赫赛汀对结肠癌裸鼠中 HER2 表达进行 SPECT/CT 成像
DOI：
10.1016/j.bbrc.2018.08.201
复制
发表时间：
2018-10-12
影响因子：
3.1
通讯作者：
Zuo, Changjing
中科院分区：
文献类型：
--
作者：
Pan, Guixia;Li, Danni;Zuo, Changjing
准确评估结直肠癌患者的HER 2状态非常重要，因为只有过表达HER 2的患者才能从抗HER 2靶向治疗中获益最多。在这项研究中，我们研究了使用I-125-Herceptin通过SPECT成像检测结肠癌中HER 2表达的可行性，该方法显示出高标记率，良好的体外稳定性和对HER 2的高结合特异性。以HER 2阳性小鼠结肠腺癌细胞系MC 38为结肠癌细胞模型，建立结肠癌裸鼠移植瘤模型。SPECT/CT显像显示，注射125-Herceptin后12 h肿瘤显影，24 h肿瘤摄取示踪剂达高峰，过量的未标记Herceptin可明显抑制肿瘤摄取示踪剂。这些结果表明，I-125-Herceptin可以被认为是一种有效的SPECT探针，用于无创检测结肠癌中HER 2的表达。(C)2018爱思唯尔公司All rights reserved.
An accurate assessment of HER2 status in patients with colorectal cancer is very important, because only the patients overexpressing HER2 can benefit most from the anti-HER2 targeted therapy. In this study, we investigated the feasibility of detecting HER2 expression in colon cancer by SPECT imaging using I-125-Herceptin, which showed high labeling rate, good in vitro stability and high binding specificity for HER2. HER2-positive mouse colon adenocarcinoma cell line (MC 38) was chosen as the colon caner cell model, and used for the establishment of colon cancer-bearing nude mice model. SPECT/CT imaging suggested that the tumors can be visualized at 12 h after the injection of I-125-Herceptin, and the uptake of tracer in tumors reached the peak at 24 h after injection, and can be attenuated significantly by pretreatment with an excess of nonlabeled Herceptin. These results indicates that I-125-Herceptin can be considered as an effective SPECT probe for the non-invasive detection of HER2 expression in colon cancer. (C) 2018 Elsevier Inc. All rights reserved.